Full-Time

Senior Downstream Product Specialist

Henry Schein

Henry Schein

10,001+ employees

Global healthcare product distributor and services

Compensation Overview

$83k - $114.2k/yr

+ Bonus

Remote in USA

Remote

Bachelor's, Master's

Category
Product (1)
Required Skills
Market Research
Product Management
Public Speaking
Financial analysis
Data Analysis

Get referred to Henry Schein

See people who can refer or advise you

Requirements
  • Typically 5 to 7 or more years of increasing responsibility in applicable professional experience.
  • Knowledge of the dental market is preferred.
  • Strong brand management skills with demonstrated ability to create, launch, and manage successful global product brands.
  • Ability to understand, interpret, and act on financial information and data contributing to business results and profitability.
  • Good research skills, including the ability to develop, implement, and interpret voice-of-customer research on brand and product insights.
  • Knowledge of content development, business process planning, and marketplace assessment.
  • Creativity, conceptualization, project management, and collaboration skills in a matrix environment.
  • Ability to plan and manage successful projects by understanding available resources, developing timelines and budgets, and assigning tasks and areas of responsibility.
  • Strong planning and organizational skills and techniques.
  • Ability to lead virtual teams.
  • Strong understanding of industry practices.
  • High proficiency with relevant tools, systems, and procedures.
  • Good decision-making, analysis, and problem-solving skills with the ability to multitask.
  • Strong verbal and written communication skills.
  • Good presentation and public-speaking skills.
  • Good interpersonal skills.
  • Good conflict-resolution skills and the ability to deliver difficult messages.
  • Ability to build partnerships at all levels within the company and begin building partnerships externally.
  • Ability to resolve complex issues effectively.
Responsibilities
  • Manage the category portfolio, including overall positioning, introducing new products, and managing resource and cost-savings projects, with oversight and support from leadership.
  • Support new product launches by gathering product information for claims and briefing documents and managing launches through completion.
  • Manage the brand trademark process in association with Henry Schein legal teams, including researching new brand names, submitting requests, tracking approvals, and maintaining usage guidelines.
  • Ensure brand trademarks and registrations remain current.
  • Support brand transitions, including facilitating project trackers and product reports covering existing and competitive products.
  • Assist with brand guideline development and maintenance.
  • Coordinate with third-party agencies and vendors to ensure project timelines are adhered to and deliverables are met.
  • Perform additional assigned duties and projects.
Desired Qualifications
  • Knowledge of the dental market.
  • Bachelor's degree or global equivalent in a related discipline.
  • Master's degree or global equivalent.
  • One or more industry certifications; professional certification may be required for advancement.

Henry Schein is a global supplier of healthcare products and services. It operates in two segments: healthcare distribution, which provides dental and medical consumables, equipment, and laboratory products to dentists, physicians, and veterinarians; and technology and value-added services, which offers practice management software, e-commerce solutions, and financial services. The company works by supplying healthcare professionals with a broad range of products and by offering software, online tools, and financing options to run their practices more efficiently. Compared with competitors, Henry Schein combines a wide product catalog with software and financial services, creating a one-stop platform for practice needs across more than 30 countries, with a strong focus on North America. Its goal is to be a trusted partner for healthcare professionals by supporting their day-to-day operations and growth through integrated distribution, technology, and financing solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Huntington, New York

Founded

1932

Get referred to Henry Schein

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $3.46 billion, and management raised full-year guidance on August 4.
  • US dental merchandise sales rose 8.3% in Q2 2026, showing share gains.
  • Value-creation savings start in Q3 2026, with Q4 earnings expected above Q3.

What critics are saying

  • Henry Schein faces ongoing antitrust litigation baggage from the Benco and Patterson dental conspiracy cases.
  • The July 30, 2026 leadership overhaul removes Ettinger, Mlotek, and Mullins, signaling instability.
  • Freight, tariff, and restructuring costs threaten margins if Q3 2026 savings slip.

What makes Henry Schein unique

  • Henry Schein serves over one million dental, medical, and veterinary customers globally.
  • Its 2026 value-creation plan targets $200 million operating income improvement and one-platform execution.
  • The company combines distribution, practice software, e-commerce, and financing in one vendor stack.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Paid Vacation

Paid Parental Leave

Short Term Disability

Health Savings Account/Flexible Spending Account

Education Benefits

Growth & Insights and Company News

Headcount

6 month growth

6%

1 year growth

6%

2 year growth

6%
Yahoo Finance
Aug 13th, 2026
Henry Schein beats Q2 estimates with $3.46B revenue, raises full-year guidance on dental growth

Henry Schein reported second-quarter results that exceeded Wall Street expectations, with revenue of $3.46 billion versus analyst estimates of $3.37 billion and adjusted EPS of $1.27 versus $1.24 expected. The company attributed the performance to accelerating internal sales growth and robust gains in its global dental merchandise segment. CEO Frederick Lowery highlighted success in converting occasional buyers into regular customers and strong market share gains in the US and Canada. The company slightly raised its full-year adjusted EPS guidance to $5.34 at the midpoint. During the earnings call, analysts questioned the sustainability of US dental consumables growth and the timing of value creation benefits. CFO Ronald South indicated most operating income improvements from these initiatives would materialise in the second half of the year.

Yahoo Finance
Aug 4th, 2026
Henry Schein raises 2026 guidance after Q2 sales hit $3.5B on dental gains

Henry Schein reported second-quarter sales of $3.5 billion, up 6.7% year-over-year, driven by 4.6% internal local-currency growth and foreign exchange benefits. The healthcare distributor raised its full-year guidance following stronger-than-expected performance. GAAP net income rose to $94 million, or $0.82 per diluted share, from $86 million a year earlier. Non-GAAP earnings reached $1.27 per share, up 15.5% from $1.10 in the prior-year period. Operating margins expanded across all segments. GAAP operating margin increased 27 basis points to 4.94%, whilst non-GAAP operating margin grew 25 basis points to 7.21%. US dental merchandise sales climbed 8.3%, including 6.5% internal growth, with the company reporting market-share gains. Chief Executive Officer Fred Lowery attributed results to operational execution and early benefits from its value-creation programme.

Yahoo Finance
Jun 23rd, 2026
Henry Schein stock gains 9.4% over 52 weeks, trails Nasdaq's 33.3% surge

Henry Schein (HSIC), a $9 billion healthcare distribution company, has underperformed the Nasdaq Composite despite recent gains. The stock is up 5.7% over three months, trailing the Nasdaq's 19.2% rise during the same period. Year-to-date, HSIC has gained 4.1% compared to the Nasdaq's 12.6% advance. The Melville, New York-based company, which supplies dental, medical and laboratory products to over one million customers, reported stronger-than-expected first-quarter results on 5 May. Adjusted earnings per share of $1.32 beat analyst estimates of $1.20, whilst revenue of $3.4 billion exceeded forecasts of $3.3 billion. Despite softer medical segment demand from a milder flu season, strength in Home Solutions and technology offerings offset the impact. The company expects full-year adjusted EPS between $5.23 and $5.37.

Fortune
Jun 19th, 2026
11 Black Fortune 500 CEOs lead companies with over $427B in combined revenues

Eleven Black CEOs currently lead Fortune 500 companies, representing just 2% of America's largest corporations but marking a record high that has doubled since 2021. These companies collectively generated $432 billion in revenue and hold a combined market value of $405 billion. The roster includes Marvin Ellison of Lowe's, the first Black CEO to lead two different Fortune 500 companies, and Thasunda Brown Duckett of TIAA, one of only two Black women currently serving as Fortune 500 chief executives. Other leaders include Peter Akwaboah (Fannie Mae), Christopher Womack (Southern Company), and Calvin Butler (Exelon). Despite comprising 14% of the overall US workforce, Black employees represent only 7% of managers and 4-5% at senior levels, according to McKinsey research. Throughout Fortune 500 history, only 28 Black CEOs have led these companies.

Yahoo Finance
May 15th, 2026
Henry Schein beats Q1 estimates with $3.37B revenue as dental market share gains offset light flu season

Henry Schein reported first-quarter revenue of $3.37 billion, beating analyst estimates of $3.34 billion, with adjusted earnings per share of $1.32 surpassing expectations of $1.22. The healthcare distributor's performance was driven by strong gains in US dental and global technology segments. CEO Frederick Lowery attributed growth to market share gains and stable dental procedure volumes, supported by merchandise price increases and investments from dental service organisations. The medical business faced headwinds from a lighter flu season affecting point-of-care diagnostics. Analysts questioned gross margin sustainability amid rising oil prices and earnings growth prospects without restructuring. Management highlighted dynamic pricing and proprietary brand growth as margin protection strategies. The company reiterated full-year adjusted EPS guidance of $5.30 at the midpoint, with market capitalisation reaching $7.86 billion.